Iceland vs Western Pacific (WHO region): Previously treated cases tested for RR-/MDR-TB
Iceland
100.0%
in 2022
Western Pacific (WHO region)
86.0%
in 2024
Iceland rank
1st
Western Pacific (WHO region) rank
3rd
Previously treated cases tested for RR-/MDR-TB over time
- Iceland
- Western Pacific (WHO region)
How they compare
Iceland currently reports 100.0% against 86.0% in Western Pacific (WHO region), a difference of 14.0%.
That makes Iceland's figure about 1.2 times Western Pacific (WHO region)'s.
The two have swapped places 4 times across 8 shared years of data; in 2005 it was Iceland ahead.
Iceland ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
Iceland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Iceland | Western Pacific (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 83.3% | 1.0% | 82.3% | Iceland |
| 2010s | 62.5% | 44.3% | 18.2% | Iceland |
| 2020s | 100.0% | 83.0% | 17.0% | Iceland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Iceland or Western Pacific (WHO region)?
- Iceland, at 100.0% against 86.0% in Western Pacific (WHO region) as of 2022.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Iceland and Western Pacific (WHO region)?
- 14.0%, with Iceland ahead.
- How many years of comparable data are there for Iceland and Western Pacific (WHO region)?
- 8 years are reported by both, from 2005 to 2022.
- How do Iceland and Western Pacific (WHO region) rank globally for previously treated cases tested for rr-/mdr-tb?
- Iceland ranks 1st and Western Pacific (WHO region) ranks 3rd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.